Actinium Pharmaceuticals (ATNM) Depreciation & Amortization (CF) (2012 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Depreciation & Amortization (CF) of $29000.0 for Q1 2026, down 38.3% year-over-year from $47000.0 in Q1 2025, and up 106.56% quarter-over-quarter from -$442000.0 in Q4 2025.
Actinium Pharmaceuticals (ATNM) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Depreciation & Amortization (CF) for 15 consecutive years, with $29000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 38.3% year-over-year to $29000.0; the TTM figure through Mar 2026 stood at $155000.0 (up 453.57% YoY), while the FY2025 annual figure was $173000.0, down 12.18% from the prior year.
- Depreciation & Amortization (CF) grew to $29000.0 in Q1 2026 per ATNM's latest filing, from -$442000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $362000.0 in Q2 2025 and bottomed at -$442000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $76764.7 across 5 years, with a median of $182000.0 in 2023.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) plunged 338.51% — and 2025, when it surged 91.53%.
- Actinium Pharmaceuticals' Depreciation & Amortization (CF) stood at $161000.0 in 2022, then slumped by 338.51% to -$384000.0 in 2023, then slipped by 6.77% to -$410000.0 in 2024, then decreased by 7.8% to -$442000.0 in 2025, then soared by 106.56% to $29000.0 in 2026.
- Business Quant data shows ATNM's Depreciation & Amortization (CF) at $29000.0 in Q1 2026, -$442000.0 in Q4 2025, and $206000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | 432,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 432,000.00 |
| Jun 30, 2026 | 432,000.00 |
| Mar 31, 2026 | 29,000.00 |
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | -442,000.00 |
| Dec 31, 2025 | -442,000.00 |
| Sep 30, 2025 | 206,000.00 |
| Sep 30, 2025 | 206,000.00 |
| Jun 30, 2025 | 362,000.00 |
| Jun 30, 2025 | 362,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | -410,000.00 |
| Dec 31, 2024 | -410,000.00 |
| Sep 30, 2024 | 202,000.00 |
| Sep 30, 2024 | 202,000.00 |
| Jun 30, 2024 | 189,000.00 |
| Jun 30, 2024 | 189,000.00 |
| Mar 31, 2024 | 216,000.00 |
| Mar 31, 2024 | 216,000.00 |